IBOV 172,060.43 ▲ 0.42% IPC MEX 72,006.05 ▲ 0.16% MERVAL 2,848,945 — — USD/BRL5.59▲ 0.09% USD/MXN18.61▲ 0.07% USD/CLP982.08▼ 0.22% USD/COP3,279▼ 0.85% USD/PEN3.41▼ 0.02% USD/ARS1,544▼ 0.03% USD/UYU40.52▲ 3.32% USD/PYG6,174▲ 3.14% USD/BOB11.63▲ 1.12% USD/DOP60.48▲ 0.05% USD/CRC446.01▲ 1.79% USD/GTQ7.64▲ 3.16% USD/HNL26.90▲ 3.29% USD/NIO36.62▲ 2.73% USD/VES902.19▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.49▲ 2.41% USD/TTD6.72▲ 2.22% EUR/BRL6.19▼ 0.60% BRENT 93.28 ▲ 0.56% WTI 86.90 ▲ 0.43% IRON ORE 161.91 — — COPPER 6.21 ▼ 0.96% GOLD 3,966 ▼ 0.87% SILVER 51.11 ▼ 1.50% SOY 1,226 ▼ 0.22% CORN 448.00 — 0.00% WHEAT 600.00 ▲ 0.08% COFFEE 265.45 ▼ 2.19% SUGAR 18.47 ▲ 2.10% ORANGE JUICE 146.60 ▼ 0.10% COTTON 82.35 ▲ 4.65% COCOA 5,061 ▲ 6.73% BEEF 218.98 ▼ 0.10% CATTLE 327.80 ▼ 0.77% LITHIUM 61.07 ▲ 1.82% PETR4 43.55 ▼ 3.11% VALE3 64.43 ▼ 0.57% ITUB4 41.72 ▲ 1.26% BBDC4 14.33 ▼ 1.44% ABEV3 15.85 ▲ 0.38% BBAS3 16.89 ▼ 1.23% B3SA3 14.80 ▲ 2.21% WEGE3 51.61 ▲ 1.30% PRIO3 61.47 ▲ 2.42% SUZB3 53.80 ▼ 1.21% RENT3 30.24 ▲ 1.51% AZZA3 15.37 ▲ 4.34% CSAN3 3.03 ▲ 13.06% RAIZ4 0.30 ▼ 98.60% PCAR3 2.54 ▼ 0.78% GMAT3 4.08 ▲ 7.09% PSSA3 45.98 ▼ 1.48% CVCB3 0.86 — 0.00% POSI3 3.32 ▲ 5.40% SLCE3 17.05 ▼ 0.23% NATU3 5.62 ▲ 1.26% BRKM5 2.92 — 0.00% RANI3 8.39 ▼ 0.71% CSNA3 4.52 ▲ 3.20% IBOV 172,060.43 ▲ 0.42% IPC MEX 72,006.05 ▲ 0.16% MERVAL 2,848,945 — — USD/BRL 5.58 ▲ 0.00% USD/MXN 18.63 ▲ 0.14% USD/CLP 982.08 ▼ 0.22% USD/COP 3,279 ▼ 0.85% USD/PEN 3.41 ▼ 0.02% USD/ARS 1,544 ▼ 0.03% USD/UYU 40.52 ▲ 3.32% USD/PYG 6,174 ▲ 3.14% USD/BOB 11.63 ▲ 0.92% USD/DOP 60.48 ▲ 0.05% USD/CRC 446.01 ▲ 1.79% USD/GTQ 7.64 ▲ 3.16% USD/HNL 26.90 ▲ 3.29% USD/NIO 36.62 ▲ 2.73% USD/VES 902.19 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.49 ▲ 2.41% USD/TTD 6.72 ▲ 2.22% EUR/BRL 6.18 ▼ 0.75% BRENT 93.28 ▲ 0.56% WTI 86.90 ▲ 0.43% IRON ORE 161.91 — — COPPER 6.21 ▼ 0.96% GOLD 3,966 ▼ 0.87% SILVER 51.11 ▼ 1.50% SOY 1,226 ▼ 0.22% CORN 448.00 — 0.00% WHEAT 600.00 ▲ 0.08% COFFEE 265.45 ▼ 2.19% SUGAR 18.47 ▲ 2.10% ORANGE JUICE 146.60 ▼ 0.10% COTTON 82.35 ▲ 4.65% COCOA 5,061 ▲ 6.73% BEEF 218.98 ▼ 0.10% CATTLE 327.80 ▼ 0.77% LITHIUM 61.07 ▲ 1.82% PETR4 43.55 ▼ 3.11% VALE3 64.43 ▼ 0.57% ITUB4 41.72 ▲ 1.26% BBDC4 14.33 ▼ 1.44% ABEV3 15.85 ▲ 0.38% BBAS3 16.89 ▼ 1.23% B3SA3 14.80 ▲ 2.21% WEGE3 51.61 ▲ 1.30% PRIO3 61.47 ▲ 2.42% SUZB3 53.80 ▼ 1.21% RENT3 30.24 ▲ 1.51% AZZA3 15.37 ▲ 4.34% CSAN3 3.03 ▲ 13.06% RAIZ4 0.30 ▼ 98.60% PCAR3 2.54 ▼ 0.78% GMAT3 4.08 ▲ 7.09% PSSA3 45.98 ▼ 1.48% CVCB3 0.86 — 0.00% POSI3 3.32 ▲ 5.40% SLCE3 17.05 ▼ 0.23% NATU3 5.62 ▲ 1.26% BRKM5 2.92 — 0.00% RANI3 8.39 ▼ 0.71% CSNA3 4.52 ▲ 3.20%
since 2009
Thursday, November 12, 2026

Covid-19 Brazil

First Coronavirus Vaccines May Not Prevent Contagion

By · · 3 min read

RIO DE JANEIRO, BRAZIL – The rush to prevent economies from collapse due to the impact of Covid-19 may result in a vaccine that prevents critical cases or death from the disease, but not coronavirus contagion.

As countries cautiously emerge from quarantine, leaders seek a preventive vaccine as a way back into pre-pandemic life.
As countries cautiously emerge from quarantine, leaders seek a preventive vaccine as a way back into pre-pandemic life.
RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

While defeating the virus is the ultimate goal, early vaccines may be limited as to what they can offer, according to Robin Shattock, a professor at Imperial College London who leads the development of an experimental vaccine.

“Is it protection against contagion?” Shattock said. “Is it protection against the disease? Is it protection against a serious disease? It’s quite possible that a vaccine that only protects against a severe disease is very useful.”

As countries cautiously emerge from quarantine, leaders seek a preventive vaccine as a way back into pre-pandemic life. Financed by billions of dollars in government investments, vaccines from little-known companies like China’s CanSino Biologics and giants like Pfizer and AstraZeneca are under development.

At least one of the most advanced experimental vaccines has already progressed to human trials, after showing an impact on critical cases – but less on contagion – in animals. Experts say this product would probably be widely used if approved, albeit with limited efficacy, until a more effective version reaches the market.

The LatAm Brief

One email, every weekday morning. What moved in Latin American markets, politics and expat life.

Yesterday’s subject line: “Petrobras to pay shareholders US$2.7 billion”

Free. We send a confirmation link first — nothing arrives until you click it. Unsubscribe with one click in any edition. If you stop opening us for 30 days we stop sending by ourselves, as we assume the interest is no longer there. See our privacy policy. We never share your email.

“Vaccines need to protect against disease, not necessarily contagion,” said Dennis Burton, immunologist and vaccine researcher at Scripps Research in La Jolla, California.

Disadvantages

However, there are disadvantages. While these vaccines have the potential to save lives, they can lead to complacency in countries wary of quarantine, said Michael Kinch, a drug development expert who is associate vice chancellor at Washington University in St. Louis.

“My guess would be that the day after someone gets immunized, they’ll think, ‘I can go back to normal life. It’s going to be okay,'” he said. “You won’t necessarily realize that you may still be susceptible to infection.”

Covid-19 is believed to be spread by asymptomatic people, and a vaccine to prevent symptoms can create an even greater number of such cases.

Vaccines are among the most effective weapons against infectious diseases and prevent up to three million deaths a year, according to the World Health Organization. However, few vaccines, if any, are 100 percent effective in all people immunized. For instance, approximately three percent of people vaccinated against measles develop a mild form of the disease and can infect others.

130 vaccines

In an attempt to address a rapidly growing threat, scientists are turning to technologies that have never been used successfully in humans. Over 130 vaccines are being developed for the prevention of Covid-19, according to the W.H.O.

Another vaccine developed by Oxford University uses an innovative approach, in which Covid genes are inserted into a different, harmless virus. They produce proteins recognized by the immune system, which increases defenses against an actual infection.

Some 25 percent of experimental vaccines listed by the W.H.O., including two already in human trials, follow the same approach as the Oxford vaccine. One of the advantages of technology is speed. AstraZeneca, in partnership with Oxford, said it will begin supplying doses to the UK in September, and will also provide the US, which helped fund its development, the following month.

Over the weekend, AstraZeneca and four countries in the European Union said they have signed an agreement to distribute hundreds of millions of doses of the vaccine.

Source: Bloomberg

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.